Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic knock-down of HDAC3 does not modify disease-related phenotypes in a mouse model of Huntington's disease.

PloS one - 1 Jan 2012

Moumné Lara, Campbell Ken, Howland David, Ouyang Yingbin, Bates Gillian P

Abstract excerpt

Huntington's disease (HD) is an autosomal dominant progressive neurodegenerative disorder caused by an expansion of a CAG/polyglutamine repeat for which there are no disease modifying treatments. In recent years, transcriptional dysregulation has emerged as a pathogenic process that appears early...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disease Models, Animal
Share to Gene Knockdown Techniques
Share to Heterozygote

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Histone Deacetylase Inhibitors

Share to Histone Deacetylases

Share to Huntington Disease

Share to Sequence Deletion

Source

Open in PubMed Open full text

Identifiers

PMID: 22347433
DOI: 10.1371/journal.pone.0031080
PMCID: PMC3275566

Genes

HDAC3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-22347433-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic knock-down of HDAC3 does not modify disease-related phenotypes in a mouse model of Huntington's disease.PMID 22347433Read ↗

Genetic knock-down of HDAC7 does not ameliorate disease pathogenesis in the R6/2 mouse model of Huntington's disease.Semantic proximity Read ↗

SAHA decreases HDAC 2 and 4 levels in vivo and improves molecular phenotypes in the R6/2 mouse model of Huntington's disease.Semantic proximity Read ↗

Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease.Semantic proximity Read ↗

Selective inhibition of histone deacetylase 1 and 3 improves motor phenotype and alleviates transcriptional dysregulation in Huntington’s disease miceSemantic proximity Read ↗

Evaluation of Histone Deacetylases as Drug Targets in Huntington’s Disease modelsStudy of HDACs in brain tissues from R6/2 and CAG140 knock-in HD mouse models and human patients and in a neuronal HD cell model.Semantic proximity Read ↗

The Effects of Selective Inhibition of Histone Deacetylase 1 and 3 in Huntington’s Disease MiceSemantic proximity Read ↗

A selective inhibitor of histone deacetylase 3 prevents cognitive deficits and suppresses striatal CAG repeat expansions in Huntington's disease mice.Semantic proximity Read ↗

Disassociation of histone deacetylase-3 from normal huntingtin underlies mutant huntingtin neurotoxicity.Semantic proximity Read ↗

Histone deacetylase knockouts modify transcription, CAG instability and nuclear pathology in Huntington disease miceSemantic proximity Read ↗

The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice.Semantic proximity Read ↗

SIRT2 ablation has no effect on tubulin acetylation in brain, cholesterol biosynthesis or the progression of Huntington's disease phenotypes in vivo.Semantic proximity Read ↗

Putting the ‘HAT’ back on survival signalling: the promises and challenges of HDAC inhibition in the treatment of neurological conditionsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.